Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Santhera Announces Completion of First 6-Month Period of Pivotal VISION-DMD Trial with .
Santhera Pharmaceuticals Holding AGMarch 3, 2021 GMT Pratteln, Switzerland, March 3, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces that the last patient has completed the last visit for the first period of the placebo-controlled pivotal VISION-DMD study with vamorolone in patients with Duchenne muscular dystrophy (DMD), conducted by partner ReveraGen Biopharma Inc. Subject to a positive 6-month topline data readout of this first study phase, this could allow for a regulatory submission to the US FDA in Q1-2022 with the potential to offer an alternative to current standard of care in DMD.
Acute flaccid myelitis: cause, diagnosis, and management thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.